The phase 2 TUXEDO-3 trial identifies the HER3-targeting antibody–drug conjugate patritumab deruxtecan as a promising new therapeutic option for patients with leptomeningeal metastasis from solid tumors.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Ozair, A. et al. Nat. Rev. Clin. Oncol. 22, 134–154 (2025).
Preusser, M. et al. Nat. Med. https://doi.org/10.1038/s41591-025-03744-1 (2025).
Yang, T. J. et al. Neuro. Oncol. 23, 134–143 (2021).
Yang, J. T. et al. J. Clin. Oncol. 40, 3858–3867 (2022).
Barbour, A. B. et al. Adv. Radiat. Oncol. 9, 101377 (2024).
Sinicrope, K. D. et al. Neuro. Oncol. Adv. 1, i8 (2019).
Kumthekar, P. U. et al. Neuro. Oncol. 25, 557–565 (2023).
Le Rhun, E. et al. Neuro. Oncol. Adv. 6, i14–i14 (2024).
Andre, F. et al. Ann. Oncol. 35, 1169–1180 (2024).
Alder, L. et al. NPJ Breast Cancer 9, 19 (2023).
Vaz Batista, M. et al. Med. 6, 100502 (2025).
O’Brien, B. J. et al. J. Clin. Oncol. 42 (Suppl. 16), 2018 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.K.A. has consulted with Genentech, Eisai, IPSEN, Seattle Genetics, Astra Zeneca, Novartis, Immunomedics, Elucida, Athenex, and Roche; she has received research funding from PUMA, Lilly, Merck, Seattle Genetics, Nektar, Tesaro, G1-Therapeutics, ZION, Novartis, Pfizer, Astra Zeneca, Elucida, Caris, Incyclix, Beigene and royalties from UptoDate.com and Jones and Bartlett. R.B. has consulted with NCODA, CareSpace Health Inc, Onviv; she has received research funding from AstraZeneca, Sermonix, Gilead, Jazz Pharmaceuticals and Genentech. A.E.D.V. has no conflicts to disclose.
Rights and permissions
About this article
Cite this article
Anders, C.K., Bansal, R. & Van Swearingen, A.E.D. A HER3-targeting antibody–drug conjugate for leptomeningeal metastasis. Nat Med 31, 2494–2495 (2025). https://doi.org/10.1038/s41591-025-03853-x
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41591-025-03853-x
